US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by NovAccess Global Inc.

News headline image
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Tickers XSNX
News headline image
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global to Participate in LD Micro Invitational XII Conference
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Tickers XSNX
News headline image
NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global, Inc.'s CEO to attend BIO Conference in New York
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Tickers XSNX
News headline image
NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
From NovAccess Global Inc.
Via AccessWire
Topics Retirement
Tickers XSNX
News headline image
NovAccess Global, Inc. Expands Advisory Board
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global, Inc. CEO Interviewed On MoneyTV
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global, Inc. to Present at the Prestigious Society for Brain Mapping and Therapeutics 2021 World Congress
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global, Inc. Announces Successful Completion of Pre-IND Meeting with FDA
From NovAccess Global Inc.
Via AccessWire
Tickers XSNX
News headline image
NovAccess Global Readies for Development of Novel Immunotherapies for Brain Tumor Patients with pre-IND meeting scheduled with the FDA and Files Form 10-K for Fiscal 2020 and Form 10-Q for FQ1/FQ2, 2021
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
Tickers XSNX